Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec Compensation
confidence 92%
filed 2026-07-24
Item 5.02
The filing discloses two compensatory arrangements: (1) approval of a new Executive Severance Plan governing future executive officer separations with specified multipliers and benefits, replacing prior Management Retention Agreements, and (2) establishment of a one-time special bonus pool for approximately 1,100 managing directors and above, with named executive officers receiving $1.9M and $850K respectively. Both are material executive compensation matters disclosed under Item 5.02(e).
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-24
Item 7.01
Modine reorganized its Climate Solutions segment into two separate operating segments (Data Centers and Commercial HVAC) effective April 1, 2026, and will report three segments beginning Q1 fiscal 2027. This is a material operational restructuring that affects how the company manages its business and deploys its 80/20 strategy, particularly to capitalize on Data Centers growth. While the filing explicitly states this is not a restatement and the Performance Technologies segment is unaffected, the segment realignment is a significant operational change that would affect investor assessment of the company's strategic direction and capital allocation.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-24
Item 2.03
Acura Pharmaceuticals entered into an amended consolidated secured promissory note with Abuse Deterrent Pharma, LLC on July 17, 2026, adding a $200,000 loan to bring total principal to approximately $10.9 million with accrued interest of ~$1.2 million. The company disclosed substantial going-concern risk, stating that absent additional financing by mid-August 2026, it will be forced to furlough/lay off employees, terminate operations, or seek bankruptcy protection.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 45%
filed 2026-07-24
Item 8.01
The filing discloses completion of a $471.8 million repurchase of convertible notes funded by a concurrent $1.474 billion equity offering of 12.5 million shares at $117.54/share. While the primary action is debt repurchase (retirement), the financing mechanism—a material registered direct offering—and the scale ($1.5B+ in aggregate capital activity) suggest this is fundamentally a capital restructuring event. The debt repurchase itself is not a new obligation but rather elimination of existing debt; however, the concurrent equity issuance creates a new direct financial obligation in the form of diluted equity. This is material to investors as it significantly alters the capital structure and shareholder base.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-07-24
Item 8.01
The Company received notification from the NYSE that it has regained compliance with continued listing standards after previously falling below the minimum market capitalization and stockholders' equity requirements of Section 802.01B. While this is technically a positive resolution, the disclosure centers on the Company's prior non-compliance status and the conditional nature of its reinstatement—the NYSE explicitly warns that falling below standards again within 12 months could trigger trading suspension procedures. This is a material delisting-risk disclosure because it reveals the Company was in jeopardy of delisting and remains under heightened monitoring.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-24
Item 5.07
This Item 5.07 filing discloses the results of AmeriServ Financial's 2026 annual shareholder meeting held on July 23, 2026, including voting outcomes on three proposals: election of three Class I directors (Richard W. Bloomingdale, David J. Hickton, and Daniel A. Onorato), an advisory vote on named executive officer compensation, and ratification of S.R. Snodgrass P.C. as independent auditor. The detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal are the core disclosure, making this a clear shareholder_vote_results event that is material to investors assessing governance and board composition.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-24
Item 2.02
AMREP Corporation issued a press release on July 24, 2026 reporting its fiscal year 2026 results ended April 30, 2026, disclosing net income of $10,288,000 ($1.91 per diluted share) and revenues of $52,847,000. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. This is material to investors as it provides the company's annual financial performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-24
Item 2.02
This is a standard quarterly earnings release for First Capital, Inc. disclosing net income of $4.8 million ($1.43 per diluted share) for Q2 2026 versus $3.8 million ($1.13 per diluted share) for Q2 2025, along with detailed results of operations and balance sheet information. The press release is attached as Exhibit 99.1 and filed under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-24
Item 3.01
Liminatus Pharma failed to regain compliance with Nasdaq's minimum bid price rule ($1 per share) and is ineligible for a second 180-day extension. The Nasdaq Hearings Panel will decide on continued listing, with no assurance the company can regain compliance.
View raw filing on EDGAR →
8-K
Governance Other
confidence 65%
filed 2026-07-24
Item 8.01
A definitive proxy statement was filed on July 13, 2026 for an annual stockholder meeting scheduled for August 3, 2026, with the primary purpose of authorizing a reverse stock split to address Nasdaq minimum bid price compliance concerns.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-24
Item 5.07
This Item 5.07 discloses the results of Hilltop Holdings' 2026 Annual Meeting of Stockholders held on July 23, 2026, where stockholders voted on three proposals: election of 13 directors, advisory approval of executive compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor. The filing presents voting results on alternative bases due to pending Ford Litigation disputing voting authority over 15.5 million shares (Diamond A Financial), demonstrating material shareholder governance activity with significant voting implications.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-24
Item 8.01
The disclosure announces FDA approval of LYTENAVA™ (bevacizumab-vikg) for wet AMD treatment, positioning it as the first and only FDA-approved ophthalmic bevacizumab formulation in the U.S. This is a major regulatory milestone and product approval event that enables commercial launch into an ~$8.5 billion market. While this is a significant operational and strategic achievement for the company, it does not fit neatly into the specific event categories (not earnings, M&A, impairment, litigation, etc.) and is best classified as an operational milestone—a material regulatory approval and product launch event.
View raw filing on EDGAR →
8-K
Bankruptcy Filing
confidence 99%
filed 2026-07-24
Item 1.03
QVC Group, Inc. filed voluntary petitions for relief under Chapter 11 of the Bankruptcy Code on April 16, 2026, and the Bankruptcy Court confirmed the Second Amended Joint Prepackaged Plan of Reorganization on July 20, 2026. The filing discloses the plan's material terms, including cancellation of all existing equity interests for no consideration and restructuring of debt claims. This is a terminal event materially threatening the registrant's continued existence, requiring classification as bankruptcy_filing under Item 1.03.
View raw filing on EDGAR →
8-K
Bankruptcy Filing
confidence 99%
filed 2026-07-24
Item 1.03
QVC Inc. and its affiliates filed voluntary petitions for relief under Chapter 11 of the Bankruptcy Code on April 16, 2026, with the Bankruptcy Court confirming the Second Amended Joint Prepackaged Plan of Reorganization on July 20, 2026. The filing discloses the plan's material terms, including cancellation of all existing equity interests for no consideration and restructuring of debt claims. This is a terminal event materially threatening the registrant's continued existence.
View raw filing on EDGAR →
8-K
Financial Other
confidence 85%
filed 2026-07-24
Item 8.01
The filing discloses the board-approved quarterly estimated net asset value (NAV) per share as of June 30, 2026, for all outstanding share and unit classes, along with detailed NAV components, valuation methodologies, and sensitivity analyses. This is a routine quarterly NAV disclosure for a non-traded REIT, which is material to investors as it reflects the estimated fair value of their holdings and is used for pricing and redemption purposes, but does not fit the specific financial event categories (earnings release, debt issuance, dividend, impairment, etc.). The disclosure is clearly financial in nature but represents a standard periodic valuation update rather than an extraordinary financial event.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 95%
filed 2026-07-24
Item 4.01
The filing discloses a change in the registrant's independent accountant: Citrin Cooperman & Company, LLP declined to stand for re-election effective July 22, 2026, and the Audit Committee appointed Malone Bailey, LLP as the new auditor. This is a classic auditor change under Item 4.01. The disclosure also notes the former auditor's reports contained an explanatory paragraph regarding substantial doubt about going concern, and identifies a material weakness in internal control over financial reporting related to income tax recording, both of which are material to investors' assessment of the company's financial reporting quality and governance.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-24
Item 3.01
Oncolytics Biotech received formal notice from Nasdaq on July 20, 2026, that its common stock failed to meet the $1.00 minimum bid price requirement for 30 consecutive business days, triggering a 180-calendar-day compliance period ending January 19, 2027. The filing explicitly discloses the delisting risk and the conditions under which the company's stock would be subject to delisting if it fails to regain compliance. This is a textbook delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-07-24
Item 2.02
Sensient Technologies disclosed Q2 2026 financial results for the quarter ended June 30, 2026, reporting revenue of $462.1 million (up 11.6%), operating income of $76.7 million (up 32.9%), and diluted EPS of $1.20 (up 36.4%), along with updated 2026 guidance. The disclosure includes a press release and updated investor presentation.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-24
Item 1.02
Lisata Therapeutics terminated its material merger agreement with Kuva Labs Inc., dated March 6, 2026, after the parent company failed to obtain financing for the tender offer. The termination triggered a $2 million termination fee obligation and materially affects the company's strategic prospects.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-07-24
Item 8.01
The Board is conducting a strategic review that explicitly contemplates reverse merger, business combination, asset sales, dissolution, or other strategic transactions, though no timetable or assurance of outcome has been provided. The scope of potential outcomes—including fundamental changes to the company's structure or existence—is material to investors.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 85%
filed 2026-07-24
Item 8.01
The filing discloses two stockholder lawsuits filed in New York Supreme Court (O'Toole v. GBTG and Lawrence v. GBTG) alleging omissions and misstatements in the Definitive Proxy Statement related to the pending merger. The complaints seek injunctions against the stockholder vote and merger consummation, rescission, and damages. Although the company denies liability and voluntarily supplemented disclosures to moot claims, the existence of active litigation seeking to enjoin a material transaction qualifies as material litigation under Item 8.01.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-24
Item 3.02
BlackRock Private Credit Fund issued 676,246.312 Institutional Class Shares for $15,887,460.36 to feeder vehicles in an unregistered sale exempt under Section 4(a)(2) and Regulation S, increasing share count and diluting existing shareholders.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-07-24
Item 8.01
BlackRock Private Credit Fund declared regular distributions to shareholders across three share classes (Institutional, Class S, and Class D) with a gross per-share amount of $0.1772, record date of July 30, 2026, and payment date of August 27, 2026.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-24
Item 5.07
This Item 5.07 disclosure reports the results of a special stockholder meeting held on July 24, 2026, where shareholders voted on three proposals: approval of warrant exercise share issuance under Nasdaq Rule 5635(d), approval of a reverse stock split (1-for-5 to 1-for-70 ratio) to maintain Nasdaq listing compliance, and authorization of meeting adjournments. All three proposals passed with clear majorities. The reverse split approval is particularly material as it directly addresses Nasdaq continued listing requirements and signals potential delisting risk mitigation.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 85%
filed 2026-07-24
The 6-K discloses early tender results for an exchange offer converting 11.000% Senior Secured Notes due 2031 into Fixed Rate Senior Secured Notes due 2032, with a concurrent consent solicitation. This constitutes a material refinancing and restructuring of existing debt obligations, which falls under debt_issuance as it involves creation of new direct financial obligations (the New Notes) and modification of the capital structure.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 90%
filed 2026-07-24
Item 1.01
Balchem entered into Amendment No. 1 to its Amended and Restated Credit Agreement on July 24, 2026, increasing the aggregate revolving commitment from $550 million to $650 million, extending the maturity date to July 24, 2031, enabling foreign borrowing, and adjusting pricing terms. This material amendment modifies the company's direct financial obligations and capital structure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-24
Item 7.01
Profound Medical announced positive clinical trial data from the Level 1 post-market CAPTAIN randomized controlled trial showing the TULSA Procedure demonstrated statistically significant superior penile length preservation compared to robotic radical prostatectomy. This is a material operational/clinical milestone for a medical device company—favorable trial results support the competitive positioning and commercial viability of the company's flagship TULSA-PRO platform. While not a traditional earnings release, restatement, or M&A event, the disclosure of significant clinical efficacy data is material to investors assessing the company's product performance and market opportunity.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 75%
filed 2026-07-24
EX-99.1
Rubico announced termination of a $30 million equity line of credit with B. Riley Principal Capital II, LLC, under which the Company had sold approximately $27.1 million of common shares. The disclosure centers on the substantial utilization of the equity issuance program ($27.1M of $30M available), which represents a material dilutive capital-raising activity.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-07-24
EX-99.2
Rubico Inc. announced entry into a letter of intent for the potential acquisition of a shipowning company (SPV) from Top Ships Inc., a related party controlled by the company's controlling shareholder. The SPV owns a high-specification MR tanker newbuilding under construction with a pre-arranged 7-year time charter at $18,750/day and 85% lease financing, with an exclusivity period through July 31, 2026 and an advance payment of $0.3 million.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-24
Item 5.02
The Compensation Committee approved special grants of performance-based restricted stock units (PSUs) to Ronald F. Clarke and Armando L. Netto on July 22, 2026. The disclosure details the grant amounts (300,000 and 28,213 PSUs respectively), performance conditions tied to stock price hurdles ($425, $450, and $475), and the vesting period through August 31, 2028. This is a compensatory arrangement for named executives intended to align their interests with shareholder value and retain their services, fitting squarely within the exec_compensation category.
View raw filing on EDGAR →
8-K
Earnings release
confidence 85%
filed 2026-07-24
The filing's primary disclosure under Item 2.02 is the announcement of second quarter 2026 financial results via press release on July 23, 2026, followed by a teleconference with analysts and investors. While Item 8.01 also discloses a quarterly dividend declaration, the earnings release is the material event that would affect a reasonable investor's assessment of the company's financial performance and condition.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-07-24
Item 3.02
VSee Health issued 1 million restricted shares and two promissory notes (totaling $50K–$125K) to settle disputes with a creditor regarding covenant breaches on an existing debt instrument, including failure to file registration statements and transfer agent instructions.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-24
The 6-K discloses board approval of a share exchange agreement with TONGYANG Life Insurance Co., Ltd., whereby Tongyang Life Insurance will be incorporated as a wholly owned subsidiary of Woori Financial Group. This constitutes a material acquisition/change of control transaction. The filing references prior disclosures and notes an expected effective date of August 11, 2026, with new share listing on August 31, 2026, confirming the materiality and substantive nature of the transaction.
View raw filing on EDGAR →
8-K
Legal Other
confidence 75%
filed 2026-07-24
Item 7.01
This disclosure reports an update on remediation of employee misconduct at Prudential's Japan subsidiaries, including a reimbursement program overseen by an independent Customer Reimbursement Committee. The filing addresses previously disclosed misconduct involving inappropriate monetary conduct by sales representatives and tracks reimbursement progress (437 of 498 original claimants processed, 2.85 billion yen of 3.08 billion yen addressed, plus 125 new eligible claimants from 365 post-January inquiries). While not a litigation or regulatory investigation per se, this is a material legal/regulatory remediation matter involving customer harm and restitution that would affect investor assessment of the company's operational and reputational risk in a significant market.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-07-24
The 6-K body discloses preliminary financial performance figures for Woori Financial Group and its subsidiary Woori Bank for the second quarter ended June 30, 2026, including revenue, operating income, net income, and earnings per share metrics on both quarterly and cumulative bases. This is a quarterly earnings announcement, material to investors assessing the registrant's financial condition and performance.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 75%
filed 2026-07-24
The board of directors resolved on July 24, 2026 to enter into a trust agreement to acquire treasury shares with a contract amount of KRW 150 billion. The stated purpose is "to enhance shareholder return and improve corporate value through the acquisition of treasury shares." Treasury share repurchases are a form of capital return to shareholders and fall within the dividend_distribution category, which includes share-repurchase programs. The material contract amount and explicit shareholder-return objective support materiality.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 95%
filed 2026-07-24
The 6-K discloses a board resolution on July 24, 2026 recommending a quarterly cash dividend of KRW 220 per common share, with a record date of August 10, 2026 and payout date of August 31, 2026. The total dividend amount is KRW 160,167,862,140. This is a routine but material capital distribution to shareholders that would affect investor assessment of the registrant's capital allocation and shareholder returns.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 75%
filed 2026-07-24
The board of directors resolved on July 24, 2026 to cancel 4,854,368 treasury shares (approximately 0.67% of outstanding shares) valued at approximately KRW 150 billion. While technically a share cancellation under Korean Commercial Code Article 343, this represents a return of capital to shareholders by reducing the share count without reducing paid-in capital, functionally equivalent to a capital distribution. The materiality threshold is met given the substantial amount involved and shareholder impact.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-07-24
Item 7.01
A jury issued an advisory verdict awarding $604 million in compensatory damages against C.H. Robinson in a trucking accident lawsuit. This is a material litigation event involving a substantial financial exposure that would affect a reasonable investor's assessment of the company's financial condition and contingent liabilities, even though the verdict remains subject to post-trial proceedings and appeal.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-24
Item 2.02
ChoiceOne Financial Services issued a press release on July 24, 2026 disclosing second quarter 2026 financial results, including net income of $12.5 million ($0.83 per diluted share), loan growth, deposit trends, asset quality metrics, and capital ratios. This is a standard quarterly earnings release attached as Exhibit 99.1 and disclosed under Item 2.02 (Results of Operations and Financial Condition), which is the typical vehicle for earnings announcements.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-07-24
Item 2.02
SLB disclosed Q2 2026 financial results on July 24, 2026, reporting revenue of $8.97 billion, GAAP EPS of $0.52, net income of $786 million, and adjusted EBITDA of $1.90 billion, with detailed segment and geographic breakdowns.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-24
Item 1.01
SBA Communications closed a $3.5 billion public offering of senior notes (4.875% due 2030, 5.150% due 2031, and 5.450% due 2033) on July 23, 2026, and entered into a new $2.5 billion senior unsecured revolving credit facility. Net proceeds were used to repay existing senior secured term loans and revolving credit facilities, including termination of a prior $2.0 billion revolving credit facility and $2.3 billion term loan.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-24
Item 2.02
HCA Healthcare issued a press release on July 24, 2026 announcing its second quarter 2026 financial results, including revenues of $20.230 billion, net income of $1.699 billion, and diluted EPS of $7.62, along with updated full-year 2026 guidance.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-07-24
Item 8.01
HCA Healthcare's Board of Directors declared a quarterly cash dividend of $0.78 per share, payable September 30, 2026 to stockholders of record as of September 16, 2026.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-24
Item 8.01
NewAmsterdam Pharma announced receipt of a positive Committee for Medicinal Products for Human Use (CHMP) opinion from the European Medicines Agency recommending marketing authorization for Ubeslo® and Evlarco® (obicetrapib-based therapies). This is a significant regulatory milestone in the clinical development and commercialization pathway for the company's lead product candidate. While not yet final approval (the European Commission decision is expected in 2H26), the positive CHMP opinion represents material progress toward a key operational and commercial objective for a late-stage biopharmaceutical company, affecting investor assessment of the company's prospects and value.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-07-24
Item 8.01
Lake Shore Bancorp's Board declared a cash dividend of $0.09 per share on July 22, 2026, payable August 12, 2026 to shareholders of record as of August 3, 2026. This is a straightforward dividend distribution disclosure, which is material to shareholders as it represents a return of capital and signals the company's capital position and dividend policy.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-24
Item 5.02
The filing discloses an amendment to CEO Daniel H. Schulman's employment agreement that modifies his compensation arrangements, including extension of his employment term through December 31, 2028, specification of base salary and incentive targets for 2028, and a long-term incentive award with a target value of at least $25 million. This is a compensatory arrangement disclosure under Item 5.02(e), distinct from an appointment or departure.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-07-24
Item 2.02
The filing discloses Gorman-Rupp's second quarter 2026 financial results via a news release dated July 24, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). The release reports record net sales of $186.1 million (up 3.9%) and record net income of $19.4 million ($0.74 per share), along with detailed segment performance, margin analysis, and year-to-date results. This is a standard quarterly earnings announcement material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-24
Item 5.02
Ronald F. Stoops was appointed as Chief Financial Officer, effective October 1, 2026, succeeding James C. Kerr. The filing emphasizes Stoops' qualifications and readiness to assume the CFO position as part of the company's succession plan.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-24
Item 3.02
Vista Credit Strategic Lending Corp. completed an unregistered sale of 150,533 shares of Class I and 7,841 shares of Class S common stock for $3.03 million pursuant to subscription agreements, relying on Section 4(a)(2) and Regulations D and S exemptions.
View raw filing on EDGAR →